CL2016001570A1 - Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas - Google Patents

Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas

Info

Publication number
CL2016001570A1
CL2016001570A1 CL2016001570A CL2016001570A CL2016001570A1 CL 2016001570 A1 CL2016001570 A1 CL 2016001570A1 CL 2016001570 A CL2016001570 A CL 2016001570A CL 2016001570 A CL2016001570 A CL 2016001570A CL 2016001570 A1 CL2016001570 A1 CL 2016001570A1
Authority
CL
Chile
Prior art keywords
activity
vortioxetine
treatment
depressive disorder
receptor antagonist
Prior art date
Application number
CL2016001570A
Other languages
English (en)
Inventor
Connie Sanchez Morillo
Gennady N Smagin
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001570(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2016001570A1 publication Critical patent/CL2016001570A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

ANTAGONISTA DE OPIOIDES CON ACTIVIDAD K PARA USARSE EN EL TRATAMIENTO DE UN TRASTORNO DEPRESIVO CON CARACTERISTICAS MENANCOLICAS; COMBINACION DE UN ANTAGONISTA DE OPIOIDES CON ACTIVIDAD K Y VORTIOXETINA PARA EL MISMO USO; Y COMPOSICION FARMACEUTICA QUE COMPRENDE UN ANTAGONISTA DE OPIOIDES CON ACTIVIDAD K Y VORTIOXETINA.
CL2016001570A 2013-12-20 2016-06-17 Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas CL2016001570A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201300710 2013-12-20
DKPA201400590 2014-10-16

Publications (1)

Publication Number Publication Date
CL2016001570A1 true CL2016001570A1 (es) 2016-12-09

Family

ID=52146489

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001570A CL2016001570A1 (es) 2013-12-20 2016-06-17 Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas

Country Status (14)

Country Link
US (1) US10376506B2 (es)
EP (1) EP3082815B1 (es)
JP (1) JP6448645B2 (es)
KR (1) KR20160093025A (es)
CN (1) CN105828821B (es)
AU (1) AU2014368548B2 (es)
CA (1) CA2933733A1 (es)
CL (1) CL2016001570A1 (es)
ES (1) ES2694352T3 (es)
IL (1) IL246253A0 (es)
MX (1) MX368870B (es)
RU (1) RU2679661C1 (es)
SG (1) SG11201604944PA (es)
WO (1) WO2015091833A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9820984B1 (en) 2016-07-01 2017-11-21 H. Lundbeck A/S Dosing regimens for fast onset of antidepressant effect
AU2019376633A1 (en) * 2018-11-06 2021-05-20 Purdue Pharma L.P. Compositions and methods for opioid antagonist delivery
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US6528518B2 (en) * 2000-12-21 2003-03-04 The Mclean Hospital Corporation Treatment of depression with kappa receptor antagonists
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
AU2003224742A1 (en) * 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
TW200803901A (en) * 2005-11-28 2008-01-16 Orexigen Therapeutics Inc Methods of treating anxiety disorders
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
WO2008066916A1 (en) 2006-11-30 2008-06-05 The Mclean Hospital Corporation Methods for the treatment of mood disorders
WO2007115975A2 (de) * 2006-04-04 2007-10-18 Holger Lars Hermann Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
US20070259939A1 (en) 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
SI2044043T2 (sl) 2006-06-16 2021-04-30 H. Lundbeck A/S 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
EP2435439B8 (en) 2009-05-25 2016-05-18 H. Lundbeck A/S Preparation of nalmefene hydrochloride from naltrexone
US20120302590A1 (en) * 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
JP5787882B2 (ja) 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤
RS55777B1 (sr) 2010-11-05 2017-07-31 H Lundbeck As Postupak za proizvodnju naltreksona
US20150342946A1 (en) * 2013-01-30 2015-12-03 Pharmorx Therapeutics, Inc. Treatments For Depression And Other Diseases With A Low Dose Agent
WO2014170351A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with mood disorder
US20160058754A1 (en) 2013-04-17 2016-03-03 H. Lundbeck A/S Nalmefene for Treatment of Patients with Anxiety Disorder

Also Published As

Publication number Publication date
MX2016007947A (es) 2016-09-09
AU2014368548B2 (en) 2019-09-19
RU2679661C1 (ru) 2019-02-12
MX368870B (es) 2019-10-21
US20160310488A1 (en) 2016-10-27
JP2016540030A (ja) 2016-12-22
SG11201604944PA (en) 2016-07-28
JP6448645B2 (ja) 2019-01-09
CA2933733A1 (en) 2015-06-25
EP3082815B1 (en) 2018-10-03
KR20160093025A (ko) 2016-08-05
WO2015091833A1 (en) 2015-06-25
EP3082815A1 (en) 2016-10-26
ES2694352T3 (es) 2018-12-20
CN105828821A (zh) 2016-08-03
CN105828821B (zh) 2019-04-09
AU2014368548A1 (en) 2016-06-30
US10376506B2 (en) 2019-08-13
RU2016123972A (ru) 2018-01-25
IL246253A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2015003440A1 (es) Composiciones de arni contra tmprss6 y métodos para su uso
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
UY35500A (es) Indazoles sustituidos con heteroarilo
AR089993A1 (es) Macrociclos peptidomimeticos
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
CL2016002873A1 (es) Composición farmacéutica para reducir el daño talámico.
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
CL2014003339A1 (es) Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112015031724A2 (pt) uso do antagonista do receptor nk-1 serlopitant em pruridos
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
IL245811B (en) Pharmaceutical preparations with hydration and lubrication activity
SV2015005126A (es) Nuevos compuestos para el tratamiento del cáncer
UY34829A (es) Nueva dosificación y formulación
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.